Table 1 |
||||||
|
Selected Trials in Previously Untreated CLL Patients |
||||||
|
Reference |
Regimen |
Phase |
No. Pts. |
CR, % |
ORR, % |
Median PFS (months) |
|
|
||||||
|
Eichhorst, 2006 |
Flu |
III |
164 |
7 |
83 |
20 |
|
Flu + Cy |
164 |
24 |
94 |
48 |
||
|
Flinn, 2007 |
Flu |
III |
137 |
5 |
59 |
19 |
|
Flu + Cy |
141 |
23 |
74 |
32 |
||
|
Catovsky, 2007 |
Chl |
III |
387 |
7 |
72 |
Not Rep |
|
Flu |
194 |
15 |
80 |
Not Rep |
||
|
Flu + Cy |
196 |
38 |
94 |
Not Rep |
||
|
Byrd, 2003 |
FR (C) |
Rand. II |
51 |
47 |
90 |
NR |
|
FR (S) |
53 |
28 |
77 |
NR |
||
|
Keating, 2005 |
FCR |
II |
300 |
72 |
94 |
NR |
|
Hallek, 2008 |
FC |
III |
409 |
23 |
85 |
32 |
|
FCR |
408 |
45 |
93 |
43 |
||
|
Kay, 2007 |
PCR |
II |
64 |
41 |
91 |
31 |
|
Kay, 2008 |
PR |
II |
33 |
30 |
79 |
12 |
|
Reynolds, 2008 |
PCR |
III |
92 |
7 |
45 |
Not Rep |
|
FCR |
92 |
17 |
58 |
Not Rep |
||
|
|
||||||
|
Key: No-Number; Flu-fludarabine; CLB-Chlorambucil; Cy-cyclophosphamide; Ritux-rituximab; FR (C) – fludarabine + rituximab, concurrent; FR (S) – fludarabine + rituximab, sequential; FCR – fludarabine, cyclophosphamide, rituximab; PCR – pentostatin, cyclophosphamide, rituximab; PR – pentostatin + rituximab; CR – complete response rate; ORR – overall response rate; PFS – progression free survival; NR – not reached; Not Rep – Not reported |
||||||
|
Maddocks and Lin Journal of Hematology & Oncology 2009 2:29 doi:10.1186/1756-8722-2-29 |
||||||
